You are here

The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Dulwich, South Australia, 5065 Australia
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Physiological Sexual Dysfunction
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- healthy pre-menopausal women

- primary female sexual arousal disorder causing distress

- on stable use of oral contraceptives

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- any other significant disease causing Female Sexual Dysfunction including psychiatric
disease

- subjects on drugs known to cause Female Sexual Dysfunction

- subjects who have given birth in the last 12 months or who are planning to become
pregnant during the study

NCT00482664
Pfizer
Completed
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Erectile Dysfunction
NCT00904748
Males
18+
Years
Braganca Paulista, SP
Erectile Dysfunction
NCT01008605
Males
40+
Years
Multiple Sites
Erectile Dysfunction, Cardiovascular Diseases, Male Urogenital Diseases
NCT01150903
Males
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Sexual Dysfunction, Physiological
  • Drug: CP-866,087
    Tablets for oral administration
  • Drug: Placebo
    Tablets for oral administration
  • Experimental: 1 mg
    Intervention: Drug: CP-866,087
  • Experimental: 10 mg
    Intervention: Drug: CP-866,087
  • Experimental: 3 mg
    Intervention: Drug: CP-866,087
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
October 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy pre-menopausal women
  • primary female sexual arousal disorder causing distress
  • on stable use of oral contraceptives

Exclusion Criteria:

  • any other significant disease causing Female Sexual Dysfunction including psychiatric disease
  • subjects on drugs known to cause Female Sexual Dysfunction
  • subjects who have given birth in the last 12 months or who are planning to become pregnant during the study
Sexes Eligible for Study: Female
20 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Denmark,   Norway,   South Africa,   Sweden
 
 
NCT00482664
A5051017
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now